Evidence map›Paper›PMID 38841537›Full record

ArticleJTO clinical and research reports2024

Brief Report: Tepotinib as a Treatment Option in

Yoshihiro Miyashita, Yosuke Hirotsu, Yuki Nagakubo, Hiroaki Kobayashi, Makoto Kawaguchi, Koki Hata, Ryota Saito, Yumiko Kakizaki, Toshiharu Tsutsui, Toshio Oyama and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yoshihiro MiyashitaLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan.
Yosuke HirotsuGenome Analysis Center, Yamanashi Central Hospital, Yamanashi, Japan.
Yuki NagakuboDivision of Genetics and Clinical Laboratory, Yamanashi Central Hospital, Yamanashi, Japan.
Hiroaki KobayashiLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan.
Makoto KawaguchiLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan.
Koki HataLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan.
Ryota SaitoLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan.
Yumiko KakizakiLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan.
Toshiharu TsutsuiLung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, Yamanashi, Japan.
Toshio OyamaPathology Division, Laboratory Department, Yamanashi Central Hospital, Yamanashi, Japan.
Masao OmataDepartment of Gastroenterology, Yamanashi Central Hospital, Yamanashi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: NSCLC is a leading cause of cancer-related mortality worldwide. Specific genetic alterations, such as Methods: We investigated patients with NSCLC and discordant results for Results: Among the 19 patients deemed Conclusions: Our findings suggest that tepotinib has comparable therapeutic effects in patients with

Indexed as

ArcherLung cancerMETOncomineTepotinib

Identifiers

PMID38841537
PMCPMC11150947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.